Open house Arzneimittelrabattverträge Rituximab, ATC L01FA01
Original notice title
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Rituximab, ATC L01FA01
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
30 / 100
Risk factors
No guaranteed purchase volume; actual business depends on patient prescriptions and price competitiveness.
Agreements may be automatically terminated if a national or regional negotiated discount contract for the same active s...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Nov 2026
- Supply of Rituximab (ATC L01FA01) under discount agreements
- Framework agreement for pharmaceutical products
Show full summary
This is an open-house (non-procurement) procedure by AOK Bayern to conclude non-exclusive framework agreements for Rabattverträge (discount agreements) for the active substance Rituximab (ATC L01FA01). Any qualified pharmaceutical company may join at any time until 05.10.2026, with contract start possible from 01.12.2024. The procedure is not subject to public procurement law; no award criteria or selection process beyond a self-declaration of reliability. Place of performance: Bavaria, Germany. No estimated value is provided.
Risks
No guaranteed purchase volume; actual business depends on patient prescriptions and price competitiveness.
Agreements may be automatically terminated if a national or regional negotiated discount contract for the same active s...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Eligibility
- Only pharmaceutical companies are eligible as potential contract partners.
Administrative
- Submission of a signed self-declaration of reliability (Eigenerklärung zur Zuverlässigkeit).
- Submission of the signed contract and appendix 'Festlegung der vertragsgegenständlichen Arzneimittel'.
Buyer
Name
AOK Bayern - Die Gesundheitskasse
Location
München, DEU
Website
Buyer profile
Identifier
DE811695320
Activity
Health
Lots (1)
LOT-0001
Open house Arzneimittelrabattverträge Rituximab, ATC L01FA01
Non-exclusive framework agreement for Rituximab discount agreements. All qualifying pharmaceutical companies can join. Contracts identical, not negotiable. Duration from 01.12.2024 to 30.11.2026. Agreements may be terminated with one month's notice or automatically superseded by other negotiated discount contracts.
Location
Duration
Category
Deadline
Award details
Selection criteria
Show original TED data
Original TED description
Siehe kurze Beschreibung
Procurement Details
- Publication date
- 16 Oct 2024
- Notice type
- Contract notice — standard
- Languages
- German
Reference metadata
- Notice subtype
- 16
- Notice version
- 1
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 627573-2024
Documents (2)
Similar tenders
Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Ganirelix (ATC-Code: H01CC01).
Czechia – Pharmaceutical products – Léčivý přípravek ATC skupiny R03DX05 s účinnou látkou OMALIZUMAB
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V über Arzneimittel mit dem Wirkstoff Denosumab Xgeva (ATC-Code nach WHO: M05BX04)
Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit der Wirkstoffkombination aus Formoterol und Beclometason, ausgenommen Dosieraerosole mit der Wirkstärke 100µg/6µg (ATC-Code: R03AK08).
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Moldova – Pharmaceutical products – Achiziționarea centralizată a Reagenților pentru Investigații Clinice, Hematologice și PATOLOGICE conform necesităților IMSP - beneficiari pentru anul 2027
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
30 / 100
Risk factors
No guaranteed purchase volume; actual business depends on patient prescriptions and price competitiveness.
Agreements may be automatically terminated if a national or regional negotiated discount contract for the same active s...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications